Several studies have demonstrated the value of artificial intelligence (AI) applications in breast cancer diagnosis. The systematic review of AI applications in breast cancer diagnosis includes several studies that compare breast cancer diagnosis and AI. However, they lack systematization, and each study appears to be conducted uniquely. The purpose and contributions of this study are to offer elaborative knowledge on the applications of AI in the diagnosis of breast cancer through citation analysis in order to categorize the main area of specialization that attracts the attention of the academic community, as well as thematic issue analysis to identify the species being researched in each category. In this study, a total number of 17,900 studies addressing breast cancer and AI published between 2012 and 2022 were obtained from these databases: IEEE, Embase: Excerpta Medica Database Guide-Ovid, PubMed, Springer, Web of Science, and Google Scholar. We applied inclusion and exclusion criteria to the search; 36 studies were identified. The vast majority of AI applications used classification models for the prediction of breast cancer. Howbeit, accuracy (99%) has the highest number of performance metrics, followed by specificity (98%) and area under the curve (0.95). Additionally, the Convolutional Neural Network (CNN) was the best model of choice in several studies. This study shows that the quantity and caliber of studies that use AI applications in breast cancer diagnosis will continue to rise annually. As a result, AI-based applications are viewed as a supplement to doctors’ clinical reasoning, with the ultimate goal of providing quality healthcare that is both affordable and accessible to everyone worldwide.

Prostate cancer is a leading cause of cancer-related morbidity and mortality worldwide, with diagnostic challenges magnified in underrepresented regions like sub-Saharan Africa. This study introduces a novel application of ConvNeXt, an advanced convolutional neural network architecture, for multi-class classification of prostate histopathological images into normal, benign, and malignant categories. The dataset, sourced from a tertiary healthcare institution in Nigeria, represents a typically underserved African population, addressing critical disparities in global diagnostic research. We also used the ProstateX dataset (2017) from The Cancer Imaging Archive (TCIA) to validate our result. A comprehensive pipeline was developed, leveraging advanced data augmentation, Grad-CAM for interpretability, and an ablation study to enhance model optimization and robustness. The ConvNeXt model achieved an accuracy of 98%, surpassing the performance of traditional CNNs (ResNet50, 93%; EfficientNet, 94%; DenseNet, 92%) and transformer-based models (ViT, 88%; CaiT, 86%; Swin Transformer, 95%; RegNet, 94%). Also, using the ProstateX dataset, the ConvNeXt model recorded 87.2%, 85.7%, 86.4%, and 0.92 as accuracy, recall, F1 score, and AUC, respectively, as validation results. Its hybrid architecture combines the strengths of CNNs and transformers, enabling superior feature extraction. Grad-CAM visualizations further enhance explainability, bridging the gap between computational predictions and clinical trust. Ablation studies demonstrated the contributions of data augmentation, optimizer selection, and learning rate tuning to model performance, highlighting its robustness and adaptability for deployment in low-resource settings. This study advances equitable health care by addressing the lack of regional representation in diagnostic datasets and employing a clinically aligned three-class classification approach. Combining high performance, interpretability, and scalability, this work establishes a foundation for future research on diverse and underrepresented populations, fostering global inclusivity in cancer diagnostics.

Tuberculosis, a deadly and contagious disease caused by Mycobacterium tuberculosis, remains a significant global public health threat. HIV co-infection significantly increases the risk of active TB recurrence and prolongs medical treatment for tuberculosis (TB). The study focuses on using advanced machine learning (ML) techniques to predict TB incidence and HIV-TB co-infection using data from the 2023 World Health Organization (WHO) Global TB burden database. The estimated rate for all types of tuberculosis per 100,000 people (E_inc_100k) and the estimated rate of HIV-positive tuberculosis incidence per 100,000 people (e_inc_tbhiv_100k) are the two main goal factors in the dataset. F1 score, accuracy, precision, recall, and the Receiver Operating Characteristic-Area Under the Curve (ROC-AUC) were among the important metrics used to evaluate the model’s performance. With 99.7% accuracy, 99.80% precision, 99.6% recall, a 99.7% F1 score, and a 99.7% ROC-AUC score, the Extreme Gradient Boosting (XGB) model outperformed other models for e_inc_100k. The e_inc_tbhiv_100k records outstanding performance from the Gradient Boosting (GB) model, with 98.58% accuracy, 98.32% precision, 98.73% recall, a 98.53% F1 score, and a 98.58% ROC-AUC score. Finally, the study aligns with the UNAIDS and WHO End TB Strategy, indicating a progression in combating TB and TB-HIV co-infection in public health workflow.

Right ventricular heart failure (RVHF) mostly occurs due to the failure of the left-side of the heart. RVHF is a serious disease that leads to swelling of the abdomen, ankles, liver, kidneys, and gastrointestinal (GI) tract. A total of 506 heart-failure subjects from the Faculty of Medicine, Cardiovascular Surgery Department, Ege University, Turkey, who suffered from a severe heart failure and are currently receiving support from a ventricular assistance device, were involved in the current study. Therefore, the current study explored the application of both the direct and inverse modelling approaches, based on the correlation analysis feature extraction performance of various pre-operative variables of the subjects, for the prediction of RVHF. The study equally employs both single and hybrid paradigms for the prediction of RVHF using different pre-operative variables. The visualized and quantitative performance of the direct and inverse modelling approach indicates the robust prediction performance of the hybrid paradigms over the single techniques in both the calibration and validation steps. Whereby, the quantitative performance of the hybrid techniques, based on the Nash–Sutcliffe coefficient (NC) metric, depicts its superiority over the single paradigms by up to 58.7%/75.5% and 80.3%/51% for the calibration/validation phases in the direct and inverse modelling approaches, respectively. Moreover, to the best knowledge of the authors, this is the first study to report the implementation of direct and inverse modelling on clinical data. The findings of the current study indicates the possibility of applying these novel hybridised paradigms for the prediction of RVHF using pre-operative variables.